CancerDrs

Lung Cancer clinical trials in New Jersey

54 actively recruiting lung cancer trials at 37 sites across New Jersey.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in New Jersey:
  • Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
  • Inspira Medical Center Mullica Hill — Mullica Hill, New Jersey
  • Penn Medicine Princeton Health — Plainsboro, New Jersey
  • Sidney Kimmel Cancer Center Washington Township — Sewell, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
  • Saint Barnabas Medical Center — Livingston, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in New Jersey:
  • Local Institution - 007-993 — Belleville, New Jersey
  • Astera Cancer Care - East Brunswick — East Brunswick, New Jersey
  • John Theurer Cancer Center — Hackensack, New Jersey
  • Local Institution - 007-975-A — Somerset, New Jersey
  • Local Institution - 007-975-B — Somerset, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in New Jersey:
  • Research Site — Camden, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in New Jersey:
  • Memorial Sloan Kettering - Basking Ridge ( Site 4056) — Basking Ridge, New Jersey
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0036) — Hackensack, New Jersey
  • Memorial Sloan Kettering - Monmouth ( Site 4057) — Middletown, New Jersey
  • Memorial Sloan Kettering - Bergen ( Site 4059) — Montvale, New Jersey
  • Atlantic Health Morristown Medical Center ( Site 4018) — Morristown, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in New Jersey:
  • Local Institution - 0507 — Morristown, New Jersey
  • Local Institution - 0346 — Paterson, New Jersey
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in New Jersey:
  • Astera Cancer Care — East Brunswick, New Jersey
  • Summit Medical Group PA — Florham Park, New Jersey
  • The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion — Paramus, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in New Jersey:
  • Atlantic Health System Morristown Medical Center ( Site 0121) — Morristown, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The first treatment is usually chemotherapy, given with another treatment that targets specific proteins on cancer cells. If the cancer gets worse, the next main tr…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07566052
Sites in New Jersey:
  • Astera Cancer Care — Edison, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung…

Sponsor: Daiichi Sankyo
NCT ID: NCT06362252
Sites in New Jersey:
  • Astera Cancer Care — East Brunswick, New Jersey
  • John Theurer Cancer Center At Hackensack Umc — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutat…

Sponsor: Taiho Oncology, Inc.
NCT ID: NCT05967689
Sites in New Jersey:
  • Memorial Sloan Kettering Cancer Center - Basking Ridge — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Cancer Center - Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Cancer Center - Bergen — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanc…

Sponsor: BioNTech SE
NCT ID: NCT06892548
Sites in New Jersey:
  • Regional Cancer Care Associates — Belleville, New Jersey
  • John Theurer Cancer Center at Hackensack UMC — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New Jersey:
  • Englewood Hospital and Medical Center (site 202) — Englewood, New Jersey
  • Summit Medical Group (site 205) — Florham Park, New Jersey
  • Atlantic Health System, Morristown Medical Center (site 124) — Morristown, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06057935
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
  • Rutgers University (Data Collection Only) — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03808337
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New Jersey:
  • John Theurer Cancer Center — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with s…

Sponsor: Alentis Therapeutics AG
NCT ID: NCT07169734
Sites in New Jersey:
  • John Theurer Cancer Center — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy can…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06780137
Sites in New Jersey:
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103) — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors har…

Sponsor: Wayshine Biopharm, Inc.
NCT ID: NCT06868485
Sites in New Jersey:
  • Hackensack Meridian Health-Southern Ocean Medical Center — Manahawkin, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest

The researchers are doing this study to find out whether hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) is a safe treatment that causes few or mild side effects in people with pleural metastases from thymic malignanci…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05354570
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited protocol activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited protocol activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Sotorasib in People With Non-Small Cell Lung Cancer

The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it beca…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06582771
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →

Showing 25 of 54 trials with sites in New Jersey. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07